GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » I-MAB (NAS:IMAB) » Definitions » Inventories, Raw Materials & Components

I-MAB (IMAB) Inventories, Raw Materials & Components : $0.00 Mil (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is I-MAB Inventories, Raw Materials & Components?

I-MAB's inventories, raw materials & components for the quarter that ended in Dec. 2024 was $0.00 Mil.


I-MAB Inventories, Raw Materials & Components Historical Data

The historical data trend for I-MAB's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

I-MAB Inventories, Raw Materials & Components Chart

I-MAB Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Inventories, Raw Materials & Components
Get a 7-Day Free Trial - - - - -

I-MAB Quarterly Data
Dec17 Sep18 Dec18 Jun19 Sep19 Dec19 Jun20 Sep20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Sep23 Dec23 Jun24 Sep24 Dec24
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

I-MAB Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.


I-MAB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » I-MAB (NAS:IMAB) » Definitions » Inventories, Raw Materials & Components
Traded in Other Exchanges
Address
2440 Research Boulevard, Suite 400, Rockville, MD, USA, 20850
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).